Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease

Creighton University

Status and phase

Withdrawn

Phase 4

Conditions

Depression

Treatments

Drug: Fluoxetine

Study type

Interventional

Funder types

Other

Identifiers

NCT00573547

05-13860

Details and patient eligibility

About

The purpose of this study is to test whether once-weekly prozac therapy leads to reduction in depression in patients requiring kidney dialysis.

Full description

Once-weekly Prozac is a psychiatric medicine, approved by the FDA for the use in treatment of psychiatric disorders. This study will test whether once-weekly Prozac leads to reduced symptoms of depression. Patients requiring dialysis often report symptoms of depression either due to the presence of major depression, a relatively common psychiatric disorder, or due to depression secondary to kidney failure.

Sex

All

Ages

19 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of chronic renal failure and end stage renal disease
Ongoing need for regular dialysis treatment
Diagnosis of depression based on DSMIV
Age tween 19-65 years

Exclusion criteria

Inability to provide informed consent
Medically or psychiatrically unstable, as defined by requiring inpatient treatment
Pregnancy, nursing or refusal to use a reliable method of birth control in women
Patients with known allergy to fluoxetine, or previous treatment failure of fluoxetine